我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

PPAR-γ C161T和CYPⅡE1基因多态性与脂肪肝中医证型的关系(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2013年06期
页码:
59-62,66
栏目:
临床研究
出版日期:
2013-12-25

文章信息/Info

Title:
The Relationship between Fatty Liver TCM Syndromes and Gene Polymorphism of PPAR-γ C161T and CYP Ⅱ E1
作者:
刘 静1卞冬雪1施军平2
1. 浙江中医药大学,浙江杭州 310015; 2. 杭州师范大学附属医院,浙江杭州 310015
Author(s):
LIU Jing1 BIAN Dong-xue1 SHI Jun-ping2
1. Zhejiang Chinese Medicine University, Hangzhou Zhejiang 310015,China; 2. The Affiliated Hospital of Hangzhou Normal University, Hangzhou Zhejiang 310015,China
关键词:
基因多态性 脂肪肝 瘀证 痰证
Keywords:
PPARγC161-T CYPⅡE1 gene polymorphism fatty liver disease silt and phlegm stasis syndrome
分类号:
R256.4
DOI:
-
文献标识码:
A
摘要:
目的 探讨PPARγC161-T、CYPⅡE1基因多态性与脂肪肝中医证型的关系。方法 将183例脂肪肝患者辨证分为瘀证组、痰证组和无证可辨组,检测183例患者及40例健康者的身体质量指数(BMI)、腰围、血压、肝肾功能、血脂、空腹血糖(FBG)、HOMA–IR(稳态胰岛素抵抗指数),检测其PPARγC161-T、CYPⅡE1的基因多态性及等位基因频率。结果 瘀证组和痰证组总甘油三脂(TG)(P<0.01)、总胆固醇(TC)(P<0.05)、低密度脂蛋白(LDL-C)(P<0.05)均高于无证可辨组。PPAR-γC161-T基因型频率及等位基因频率在脂肪肝各证型组与对照组中无统计学差异(P>0.05)。CYPⅡE1基因型频率及等位基因频率在脂肪肝各证型组与对照组中有统计学差异(P<0.05)。结论 脂质代谢紊乱及相关改变与脂肪肝痰、瘀证密切相关。CYPⅡE1基因多态性可能在脂肪肝痰瘀证的形成以及转化中起着决定性的作用。
Abstract:
Objective To explore the relationship between fatty liver TCM syndromes and gene polymorphism of PPAR-γ C161T and CYP Ⅱ E1. Methods 183 patients are differentiate by Chinese traditional medicine, BMI, WC, BP, FINS, FBG, HOMA -IR, liver and kidney function, serum lipid. PPARγC161-T, CYP Ⅱ E1 gene polymorphism and allele frequencies are detected in 183 cases of patients and 40 healthy persons. Results TG, TC, LDL-C of silt syndrome group and phlegm stasis syndrome group were higher than those without a discernible group(P<0. 05). Compared with the control group, genotype and allele frequencies of PPAR-γC161-T of each fatty liver syndrome groups have no significant difference(P>0. 05), while genotype and allele frequencies of CYP Ⅱ E1 of each fatty liver syndrome group have significantly difference(P<0. 05). Conclusion Disorder of lipid metabolism and associated changes closely relate to silt and phlegm stasis syndrome. Gene polymorphism CYP Ⅱ E1 may play an important role in the formation and transformation of silt and phlegm stasis syndrome in fatty liver disease.

参考文献/References

[1] Fan JG,Farrell GC. Epidemiology of alcoholic and non-alcoholic fatty liver disease in China[J]. Gastroenterol Hepatol,2009,50(1):204-210.
[2] Wang YX,Lee CH,Tiep S,et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity[J]. Cell,2003,113(2):159-170.
[3] Chalasani N,Gorski C,Asghar M,et al. Hepatic cytochrome P4502E1 activity in nondiabetic patients with nonalcoholic steatohepatitis[J]. Hepatology,2003,37(3):544-550.
[4] 潘丰满,杨钦河,沈英森,等. 祛湿活血法为主在脂肪肝治疗中的应用[J]. 四川中医,2004,22(6):23.
[5] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 中华肝脏病杂志,2010,18(3):163-166.
[6] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 酒精性肝病诊疗指南[J]. 中华肝脏病杂志,2010,18(3):167-170.
[7] 国家技术监督局. 中华人民共和国国家标准·中医临床诊疗术语[S]. 北京:中国标准出版社,1997: 12.
[8] Vidal F,Lorenzo A,Auguet T,et al. Genetic polymorphisms of ADH2,ADH3,CYP4502E1 Dra-I and Pst-I,and ALDH2 in Spanish men:lack of association with alcoholism and alcoholic liver disease[J]. Hepatology,2004,41(5):744-750.
[9] Song J,Sakatsume M,Narita I,et al. Poliferator-activated receptor γ C161T polymorphisms and survival of Japanese patients with immunoglobulin A nephropathy[J]. Clin Genet,2003,64(5):398.
[10] 孙建芝,牛晓亚,韩丽华,等. 痰浊证微观辨证指标的实验研究[J]. 河南中医,1996,16(2):21-22.
[11] 李靖涛,朴云峰,孟祥伟. CYPⅡE1基因多态性与酒精性脂肪肝[J]. 临床肝胆病杂志,2003,19(1):48-49.
[12] 李靖涛,赵洪川. 细胞色素P450ⅡE1基因多态性在非酒精性脂肪肝中的意义[J]. 中华肝脏病杂志,2003,11(2):116.
[13] Wang XL,Oosterhof J,Duarte N,et al. Peroxisome proliferators-activatorγC161 T polymorphism and coronary heart disease[J]. Cardiovasc Res,1999,44(3):588-594.
[14] Y Hui,L Yu-Yuan,N Yu-Qiang,et al. Effect of peroxisome proliferators activated receptors-γ and co-activator-1α genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people[J]. Liver International. 2007,28(3):355-392.

备注/Memo

备注/Memo:
基金项目: 浙江省医药卫生科技项目(NO:2011KYA132) 收稿日期: 2013 - 11 - 07 修回日期: 2013 -11 - 27 作者简介: 刘静(1987~),女,湖北宜昌人,在读硕士研究生,主要从事脂肪肝的基础与临床研究。 △通信作者:施军平, E-mail:13957121199@126.com
更新日期/Last Update: 2013-12-20